Dalton Pharma Services, a pharmaceutical manufacturing company, has recently commissioned 3P innovation to design and construct a fully automated state-of-the-art high-speed aseptic powder filling line to expedite drug production in a more compliant, efficient, and economical manner.
 
This strategic investment expands the collaboration between the two companies and enables Toronto-based Dalton to effectively meet its current and future business needs for the supply of aseptic filling technology.
 
Jixing Wang, President at Dalton, said, “Due to increasing customer demand, we needed to further enhance our competencies in speed, quality and flexibility. Having maximized our capacity in aseptic powder fill/finish, we sought innovative technology to support our growth. This investment will reinforce Dalton’s market position as a leading partner in aseptic powder filling.”
 
Dalton identified the Robotic Fill-Finish (RFF) Cell from 3P innovation as being an ideal solution based on the feasibility studies of several difficult to handle powders. Other factors of consideration included the increased sterility assurance, reduced risk of product failure and enhanced Annex 1 compliance.
 
The acquisition of 3P innovation’s RFF Cell enables Dalton to address larger segments of the pharmaceutical market and serve customers with greater global patient populations.
The new system comprises fully integrated isolators with multiple linked process chambers that have been designed to provide a compact integrated solution for ready-to-use (RTU) tubs. With six chambers, filling, stoppering, capping and crimping will all be done automatically. 
 
Technically able to handle both powder and liquid media filling applications, 3P innovation announced that the first commercial unit has been sold and is currently under construction.